Successful Unrelated Cord Blood Transplantation in an Infant with Wiskott-Aldrich Syndrome following Recurrent Cytomegalovirus Disease

International Journal of Hematology

Volumn 78, Issue 5, 2003, Pages 457-460

  Kaneko, Michiya ^a   Watanabe, Tsutomu ^a   Watanabe, Hiroyoshi ^a   Kimura, Masahiro ^b   Suzuya, Hiroko ^a   Okamoto, Yasuhiro ^a   Nakagawa, Ryuji ^a   Kuroda, Yasuhiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TAKAMATSU RED CROSS HOSPITAL   (Japan)

Author keywords

Cord blood transplantation; Cytomegalovirus pneumonia; Wiskott Aldrich syndrome

Indexed keywords

BIOLOGICAL MARKER; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GANCICLOVIR; HLA ANTIGEN; METHOTREXATE; MITOGENIC AGENT; PHYTOHEMAGGLUTININ; THYMOCYTE ANTIBODY; VIRUS ANTIGEN; ZETBULIN;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HLA MATCHING; HUMAN; LONG TERM CARE; MALE; NEUTROPHIL; OUTCOMES RESEARCH; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRESCHOOL CHILD; RECURRENT INFECTION; THROMBOCYTE COUNT; UMBILICAL CORD BLOOD; VIRUS ISOLATION; VIRUS PNEUMONIA; VIRUS REACTIVATION; WISKOTT ALDRICH SYNDROME;

EID: 0348109351     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983821     Document Type: Article

References (17)

1. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876-885.
2. Derry JM, Ochs HD, Francke U, et al. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994;78:635-644.
3. Klein C, Nguryn D, Liu C, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood. 2003;101:2159-2166.
4. Filipovich AH, Stone JV, Tomany SC, et al. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001;97:1598-1603.
5. Kernan NA, Schroeder ML, Ciavarella D, et al. Umbilical cord blood infusion in a patient for correction of Wiskott-Aldrich syndrome. Blood Cells. 1994;20:245-248.
6. Knutsen AP, Steffen M, Wassmer K, Wall DA. Umbilical cord blood transplantation in Wiskott Aldrich syndrome. J Pediatr. 2003;142:519-523.
7. Zaia JA. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29:633-638.
8. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;334:1038-1044.
9. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cell for transplantation. Blood. 1997;90:4665-4678.
10. Grewal SS, Baker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood. 2003;101:4233-4244.
11. Knutsen AP, Wall DA. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: two-year experience. J Clin Immunol. 2000;20:466-476.
12. Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. Blood. 2000;96:2703-2711.
13. Moretta A, Maccario R, Fagioli F, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 2001;29:371-379.
14. Burns LJ, Miller W, Kandaswarny C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. Bone Marrow Transplant. 2002;30:945-951.
15. Verdonck LF, van den Hoek MR, Rozenberg-Arska M, Dekker AW. A risk adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplant. Clin Infect Dis. 1997;24:901-907.
16. Tanaka Y, Kanda Y, Kami M, et al. Monitoring of cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:315-319.
17. Junghanss C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 2002;99:1978-1985.